• Je něco špatně v tomto záznamu ?

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

L. Melchior, A. Hirschmann, P. Hofman, C. Bontoux, A. Concha, S. Mrabet-Dahbi, P. Vannuffel, E. Watkin, M. Putzová, S. Scarpino, A. Cayre, P. Martin, R. Stoehr, A. Hartmann

. 2024 ; 484 (4) : 677-686. [pub] 20240316

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie, hodnotící studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014440
E-zdroje Online Plný text

NLK ProQuest Central od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2003-01-01 do Před 1 rokem

Odkazy

PubMed 38492039
DOI 10.1007/s00428-024-03778-9
Knihovny.cz E-zdroje

The current study assessed the performance of the fully automated RT-PCR-based IdyllaTM GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK, ROS1, RET, and MET exon 14 rearrangements, in a routine clinical setting involving 12 European clinical centers. The IdyllaTM GeneFusion Assay detects fusions using fusion-specific as well as expression imbalance detection, the latter enabling detection of uncommon fusions not covered by fusion-specific assays. In total, 326 archival aNSCLC formalin-fixed paraffin-embedded (FFPE) samples were included of which 44% were resected specimen, 46% tissue biopsies, and 9% cytological specimen. With a total of 179 biomarker-positive cases (i.e., 85 ALK, 33 ROS1, 20 RET fusions and 41 MET exon 14 skipping), this is one of the largest fusion-positive datasets ever tested. The results of the IdyllaTM GeneFusion Assay were compared with earlier results of routine reference technologies including fluorescence in situ hybridization, immunohistochemistry, reverse-transcription polymerase chain reaction, and next-generation sequencing, establishing a high sensitivity/specificity of 96.1%/99.6% for ALK, 96.7%/99.0% for ROS1, 100%/99.3% for RET fusion, and 92.5%/99.6% for MET exon 14 skipping, and a low failure rate (0.9%). The IdyllaTM GeneFusion Assay was found to be a reliable, sensitive, and specific tool for routine detection of ALK, ROS1, RET fusions and MET exon 14 skipping. Given its short turnaround time of about 3 h, it is a time-efficient upfront screening tool in FFPE samples, supporting rapid clinical decision making. Moreover, expression-imbalance-based detection of potentially novel fusions may be easily verified with other routine technologies without delaying treatment initiation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014440
003      
CZ-PrNML
005      
20240905133557.0
007      
ta
008      
240725s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-024-03778-9 $2 doi
035    __
$a (PubMed)38492039
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Melchior, Linea $u Department of Pathology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark. linea.cecilie.melchior@regionh.dk $u , Copenhagen, Denmark. linea.cecilie.melchior@regionh.dk
245    10
$a Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC / $c L. Melchior, A. Hirschmann, P. Hofman, C. Bontoux, A. Concha, S. Mrabet-Dahbi, P. Vannuffel, E. Watkin, M. Putzová, S. Scarpino, A. Cayre, P. Martin, R. Stoehr, A. Hartmann
520    9_
$a The current study assessed the performance of the fully automated RT-PCR-based IdyllaTM GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK, ROS1, RET, and MET exon 14 rearrangements, in a routine clinical setting involving 12 European clinical centers. The IdyllaTM GeneFusion Assay detects fusions using fusion-specific as well as expression imbalance detection, the latter enabling detection of uncommon fusions not covered by fusion-specific assays. In total, 326 archival aNSCLC formalin-fixed paraffin-embedded (FFPE) samples were included of which 44% were resected specimen, 46% tissue biopsies, and 9% cytological specimen. With a total of 179 biomarker-positive cases (i.e., 85 ALK, 33 ROS1, 20 RET fusions and 41 MET exon 14 skipping), this is one of the largest fusion-positive datasets ever tested. The results of the IdyllaTM GeneFusion Assay were compared with earlier results of routine reference technologies including fluorescence in situ hybridization, immunohistochemistry, reverse-transcription polymerase chain reaction, and next-generation sequencing, establishing a high sensitivity/specificity of 96.1%/99.6% for ALK, 96.7%/99.0% for ROS1, 100%/99.3% for RET fusion, and 92.5%/99.6% for MET exon 14 skipping, and a low failure rate (0.9%). The IdyllaTM GeneFusion Assay was found to be a reliable, sensitive, and specific tool for routine detection of ALK, ROS1, RET fusions and MET exon 14 skipping. Given its short turnaround time of about 3 h, it is a time-efficient upfront screening tool in FFPE samples, supporting rapid clinical decision making. Moreover, expression-imbalance-based detection of potentially novel fusions may be easily verified with other routine technologies without delaying treatment initiation.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x genetika $x patologie $7 D002289
650    12
$a protoonkogenní proteiny c-ret $x genetika $7 D051096
650    12
$a anaplastická lymfomová kináza $x genetika $7 D000077548
650    12
$a nádory plic $x genetika $x patologie $7 D008175
650    12
$a tyrosinkinasy $x genetika $7 D011505
650    12
$a protoonkogenní proteiny c-met $x genetika $7 D019859
650    12
$a exony $x genetika $7 D005091
650    12
$a protoonkogenní proteiny $x genetika $7 D011518
650    12
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a nádorové biomarkery $x genetika $x analýza $7 D014408
650    _2
$a genová přestavba $7 D015321
650    _2
$a hybridizace in situ fluorescenční $x metody $7 D017404
650    _2
$a multiplexová polymerázová řetězová reakce $7 D060885
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a hodnotící studie $7 D023362
700    1_
$a Hirschmann, Astrid $u Department of Pathology, Luzerner Kantonsspital, Lucerne, Switzerland
700    1_
$a Hofman, Paul $u Laboratory of Clinical and Experimental Pathology, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France $u Hospital-integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France $u FHU OncoAge, IHU RespirERA, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France
700    1_
$a Bontoux, Christophe $u Laboratory of Clinical and Experimental Pathology, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France $u Hospital-integrated Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France $u FHU OncoAge, IHU RespirERA, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France
700    1_
$a Concha, Angel $u Complejo Hospitalario de A Coruña, Corunna, Spain
700    1_
$a Mrabet-Dahbi, Salima $u Institut für Pathologie, Klinikum Kassel, Kassel, Germany
700    1_
$a Vannuffel, Pascal $u Institut de Pathologie et de Génétique, Gosselies, Belgium
700    1_
$a Watkin, Emmanuel $u Cabinet de Pathologie Cypath, Lyon, France
700    1_
$a Putzová, Martina $u Bioptická Laboratoř, Pilsen, Czechia
700    1_
$a Scarpino, Stefania $u Department of Clinical and Molecular Medicine, Pathology Unit, St. Andrea University Hospital, University of Rome La Sapienza, Rome, Italy
700    1_
$a Cayre, Anne $u UF de Pathologie, Centre Jean Perrin, INSERM U1240, Clermont-Ferrand, France
700    1_
$a Martin, Paloma $u Molecular Pathology Group, Department of Pathology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, Spain $u Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
700    1_
$a Stoehr, Robert $u Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany $u Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany $u Bavarian Cancer Research Center (BZKF), Erlangen, Germany
700    1_
$a Hartmann, Arndt $u Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany $u Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany $u Bavarian Cancer Research Center (BZKF), Erlangen, Germany
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 484, č. 4 (2024), s. 677-686
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38492039 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133551 $b ABA008
999    __
$a ok $b bmc $g 2143912 $s 1226306
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 484 $c 4 $d 677-686 $e 20240316 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace